These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18275560)

  • 1. Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice.
    Laloux C; Derambure P; Houdayer E; Jacquesson JM; Bordet R; Destée A; Monaca C
    J Sleep Res; 2008 Mar; 17(1):101-10. PubMed ID: 18275560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vigilance states in a parkinsonian model, the MPTP mouse.
    Monaca C; Laloux C; Jacquesson JM; Gelé P; Maréchal X; Bordet R; Destée A; Derambure P
    Eur J Neurosci; 2004 Nov; 20(9):2474-8. PubMed ID: 15525288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A; Lang AE; Shapiro CM
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
    J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
    Szego ÉM; Gerhardt E; Kermer P; Schulz JB
    Neurobiol Dis; 2012 Jan; 45(1):591-600. PubMed ID: 22001606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
    Archer T; Fredriksson A
    J Neural Transm (Vienna); 2003 Feb; 110(2):183-200. PubMed ID: 12589577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model.
    Barraud Q; Lambrecq V; Forni C; McGuire S; Hill M; Bioulac B; Balzamo E; Bezard E; Tison F; Ghorayeb I
    Exp Neurol; 2009 Oct; 219(2):574-82. PubMed ID: 19635479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D(1)/D(2) receptor-targeting L-stepholidine, an active ingredient of the Chinese herb Stephonia, induces non-rapid eye movement sleep in mice.
    Qiu MH; Qu WM; Xu XH; Yan MM; Urade Y; Huang ZL
    Pharmacol Biochem Behav; 2009 Nov; 94(1):16-23. PubMed ID: 19604496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restorative effects of glutamate antagonists in experimental parkinsonism.
    Archer T; Palomo T; Fredriksson A
    Amino Acids; 2002; 23(1-3):71-85. PubMed ID: 12373521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
    [No Abstract]   [Full Text] [Related]  

  • 13. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DA agonists -- ergot derivatives: lisuride: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S74-8. PubMed ID: 12211144
    [No Abstract]   [Full Text] [Related]  

  • 15. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.
    Blume SR; Cass DK; Tseng KY
    Exp Neurol; 2009 Sep; 219(1):208-11. PubMed ID: 19460369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
    Hyacinthe C; Barraud Q; Tison F; Bezard E; Ghorayeb I
    Neurobiol Dis; 2014 Mar; 63():20-4. PubMed ID: 24211719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
    Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
    Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
    Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
    Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.